OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment
• Anti-OX40 is a promising antibody that is currently in early phase clinical trials for the treatment of cancer. • OX40 is highly expressed in the tumor infiltrating lymphocytes of patients with head and neck squamous cell carcinoma. • Preclinical models have suggested synergy between anti-OX40 and...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Bell, R. Bryan [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole - 2012transfer abstract, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:52 ; year:2016 ; pages:1-10 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.oraloncology.2015.11.009 |
|---|
| Katalog-ID: |
ELV029471567 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV029471567 | ||
| 003 | DE-627 | ||
| 005 | 20230623201337.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2015.11.009 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016002000024.pica |
| 035 | |a (DE-627)ELV029471567 | ||
| 035 | |a (ELSEVIER)S1368-8375(15)00387-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 650 |q VZ |
| 084 | |a 85.03 |2 bkl | ||
| 084 | |a 31.80 |2 bkl | ||
| 084 | |a 54.80 |2 bkl | ||
| 084 | |a 50.03 |2 bkl | ||
| 100 | 1 | |a Bell, R. Bryan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment |
| 264 | 1 | |c 2016 | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Anti-OX40 is a promising antibody that is currently in early phase clinical trials for the treatment of cancer. • OX40 is highly expressed in the tumor infiltrating lymphocytes of patients with head and neck squamous cell carcinoma. • Preclinical models have suggested synergy between anti-OX40 and anti-PD1, anti-OX40 and anti-CTLA-4, as well as anti-OX40 and anti-PDL1. • Anti-OX40 is currently being tested in early phase human clinical trials, both as monotherapy and in combination with other immunotherapies, in head and neck squamous cell carcinoma. | ||
| 650 | 7 | |a OX40 |2 Elsevier | |
| 650 | 7 | |a Oral cancer |2 Elsevier | |
| 650 | 7 | |a Immunotherapy |2 Elsevier | |
| 650 | 7 | |a Head and neck cancer |2 Elsevier | |
| 650 | 7 | |a CTLA-4 |2 Elsevier | |
| 650 | 7 | |a PD-1 |2 Elsevier | |
| 700 | 1 | |a Leidner, Rom S. |4 oth | |
| 700 | 1 | |a Crittenden, Marka R. |4 oth | |
| 700 | 1 | |a Curti, Brendan D. |4 oth | |
| 700 | 1 | |a Feng, Zipei |4 oth | |
| 700 | 1 | |a Montler, Ryan |4 oth | |
| 700 | 1 | |a Gough, Michael J. |4 oth | |
| 700 | 1 | |a Fox, Bernard A. |4 oth | |
| 700 | 1 | |a Weinberg, Andrew D. |4 oth | |
| 700 | 1 | |a Urba, Walter J. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |d 2012transfer abstract |g Amsterdam [u.a.] |w (DE-627)ELV011194073 |
| 773 | 1 | 8 | |g volume:52 |g year:2016 |g pages:1-10 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.oraloncology.2015.11.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-MAT | ||
| 936 | b | k | |a 85.03 |j Methoden und Techniken der Betriebswirtschaft |q VZ |
| 936 | b | k | |a 31.80 |j Angewandte Mathematik |q VZ |
| 936 | b | k | |a 54.80 |j Angewandte Informatik |q VZ |
| 936 | b | k | |a 50.03 |j Methoden und Techniken der Ingenieurwissenschaften |q VZ |
| 951 | |a AR | ||
| 952 | |d 52 |j 2016 |h 1-10 |g 10 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
r b b rb rbb |
|---|---|
| matchkey_str |
bellrbryanleidnerromscrittendenmarkarcur:2016----:x0inlnihaadekqaoselacnmoecmnimnsprsin |
| hierarchy_sort_str |
2016 |
| bklnumber |
85.03 31.80 54.80 50.03 |
| publishDate |
2016 |
| allfields |
10.1016/j.oraloncology.2015.11.009 doi GBVA2016002000024.pica (DE-627)ELV029471567 (ELSEVIER)S1368-8375(15)00387-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Bell, R. Bryan verfasserin aut OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment 2016 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-OX40 is a promising antibody that is currently in early phase clinical trials for the treatment of cancer. • OX40 is highly expressed in the tumor infiltrating lymphocytes of patients with head and neck squamous cell carcinoma. • Preclinical models have suggested synergy between anti-OX40 and anti-PD1, anti-OX40 and anti-CTLA-4, as well as anti-OX40 and anti-PDL1. • Anti-OX40 is currently being tested in early phase human clinical trials, both as monotherapy and in combination with other immunotherapies, in head and neck squamous cell carcinoma. OX40 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Head and neck cancer Elsevier CTLA-4 Elsevier PD-1 Elsevier Leidner, Rom S. oth Crittenden, Marka R. oth Curti, Brendan D. oth Feng, Zipei oth Montler, Ryan oth Gough, Michael J. oth Fox, Bernard A. oth Weinberg, Andrew D. oth Urba, Walter J. oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:52 year:2016 pages:1-10 extent:10 https://doi.org/10.1016/j.oraloncology.2015.11.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 52 2016 1-10 10 045F 610 |
| spelling |
10.1016/j.oraloncology.2015.11.009 doi GBVA2016002000024.pica (DE-627)ELV029471567 (ELSEVIER)S1368-8375(15)00387-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Bell, R. Bryan verfasserin aut OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment 2016 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-OX40 is a promising antibody that is currently in early phase clinical trials for the treatment of cancer. • OX40 is highly expressed in the tumor infiltrating lymphocytes of patients with head and neck squamous cell carcinoma. • Preclinical models have suggested synergy between anti-OX40 and anti-PD1, anti-OX40 and anti-CTLA-4, as well as anti-OX40 and anti-PDL1. • Anti-OX40 is currently being tested in early phase human clinical trials, both as monotherapy and in combination with other immunotherapies, in head and neck squamous cell carcinoma. OX40 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Head and neck cancer Elsevier CTLA-4 Elsevier PD-1 Elsevier Leidner, Rom S. oth Crittenden, Marka R. oth Curti, Brendan D. oth Feng, Zipei oth Montler, Ryan oth Gough, Michael J. oth Fox, Bernard A. oth Weinberg, Andrew D. oth Urba, Walter J. oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:52 year:2016 pages:1-10 extent:10 https://doi.org/10.1016/j.oraloncology.2015.11.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 52 2016 1-10 10 045F 610 |
| allfields_unstemmed |
10.1016/j.oraloncology.2015.11.009 doi GBVA2016002000024.pica (DE-627)ELV029471567 (ELSEVIER)S1368-8375(15)00387-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Bell, R. Bryan verfasserin aut OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment 2016 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-OX40 is a promising antibody that is currently in early phase clinical trials for the treatment of cancer. • OX40 is highly expressed in the tumor infiltrating lymphocytes of patients with head and neck squamous cell carcinoma. • Preclinical models have suggested synergy between anti-OX40 and anti-PD1, anti-OX40 and anti-CTLA-4, as well as anti-OX40 and anti-PDL1. • Anti-OX40 is currently being tested in early phase human clinical trials, both as monotherapy and in combination with other immunotherapies, in head and neck squamous cell carcinoma. OX40 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Head and neck cancer Elsevier CTLA-4 Elsevier PD-1 Elsevier Leidner, Rom S. oth Crittenden, Marka R. oth Curti, Brendan D. oth Feng, Zipei oth Montler, Ryan oth Gough, Michael J. oth Fox, Bernard A. oth Weinberg, Andrew D. oth Urba, Walter J. oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:52 year:2016 pages:1-10 extent:10 https://doi.org/10.1016/j.oraloncology.2015.11.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 52 2016 1-10 10 045F 610 |
| allfieldsGer |
10.1016/j.oraloncology.2015.11.009 doi GBVA2016002000024.pica (DE-627)ELV029471567 (ELSEVIER)S1368-8375(15)00387-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Bell, R. Bryan verfasserin aut OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment 2016 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-OX40 is a promising antibody that is currently in early phase clinical trials for the treatment of cancer. • OX40 is highly expressed in the tumor infiltrating lymphocytes of patients with head and neck squamous cell carcinoma. • Preclinical models have suggested synergy between anti-OX40 and anti-PD1, anti-OX40 and anti-CTLA-4, as well as anti-OX40 and anti-PDL1. • Anti-OX40 is currently being tested in early phase human clinical trials, both as monotherapy and in combination with other immunotherapies, in head and neck squamous cell carcinoma. OX40 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Head and neck cancer Elsevier CTLA-4 Elsevier PD-1 Elsevier Leidner, Rom S. oth Crittenden, Marka R. oth Curti, Brendan D. oth Feng, Zipei oth Montler, Ryan oth Gough, Michael J. oth Fox, Bernard A. oth Weinberg, Andrew D. oth Urba, Walter J. oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:52 year:2016 pages:1-10 extent:10 https://doi.org/10.1016/j.oraloncology.2015.11.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 52 2016 1-10 10 045F 610 |
| allfieldsSound |
10.1016/j.oraloncology.2015.11.009 doi GBVA2016002000024.pica (DE-627)ELV029471567 (ELSEVIER)S1368-8375(15)00387-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Bell, R. Bryan verfasserin aut OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment 2016 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-OX40 is a promising antibody that is currently in early phase clinical trials for the treatment of cancer. • OX40 is highly expressed in the tumor infiltrating lymphocytes of patients with head and neck squamous cell carcinoma. • Preclinical models have suggested synergy between anti-OX40 and anti-PD1, anti-OX40 and anti-CTLA-4, as well as anti-OX40 and anti-PDL1. • Anti-OX40 is currently being tested in early phase human clinical trials, both as monotherapy and in combination with other immunotherapies, in head and neck squamous cell carcinoma. OX40 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Head and neck cancer Elsevier CTLA-4 Elsevier PD-1 Elsevier Leidner, Rom S. oth Crittenden, Marka R. oth Curti, Brendan D. oth Feng, Zipei oth Montler, Ryan oth Gough, Michael J. oth Fox, Bernard A. oth Weinberg, Andrew D. oth Urba, Walter J. oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:52 year:2016 pages:1-10 extent:10 https://doi.org/10.1016/j.oraloncology.2015.11.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 52 2016 1-10 10 045F 610 |
| language |
English |
| source |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:52 year:2016 pages:1-10 extent:10 |
| sourceStr |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:52 year:2016 pages:1-10 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Methoden und Techniken der Betriebswirtschaft Angewandte Mathematik Angewandte Informatik Methoden und Techniken der Ingenieurwissenschaften |
| institution |
findex.gbv.de |
| topic_facet |
OX40 Oral cancer Immunotherapy Head and neck cancer CTLA-4 PD-1 |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| authorswithroles_txt_mv |
Bell, R. Bryan @@aut@@ Leidner, Rom S. @@oth@@ Crittenden, Marka R. @@oth@@ Curti, Brendan D. @@oth@@ Feng, Zipei @@oth@@ Montler, Ryan @@oth@@ Gough, Michael J. @@oth@@ Fox, Bernard A. @@oth@@ Weinberg, Andrew D. @@oth@@ Urba, Walter J. @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011194073 |
| dewey-sort |
3610 |
| id |
ELV029471567 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029471567</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623201337.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2015.11.009</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016002000024.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029471567</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(15)00387-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bell, R. Bryan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Anti-OX40 is a promising antibody that is currently in early phase clinical trials for the treatment of cancer. • OX40 is highly expressed in the tumor infiltrating lymphocytes of patients with head and neck squamous cell carcinoma. • Preclinical models have suggested synergy between anti-OX40 and anti-PD1, anti-OX40 and anti-CTLA-4, as well as anti-OX40 and anti-PDL1. • Anti-OX40 is currently being tested in early phase human clinical trials, both as monotherapy and in combination with other immunotherapies, in head and neck squamous cell carcinoma.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">OX40</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oral cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Head and neck cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CTLA-4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD-1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leidner, Rom S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Crittenden, Marka R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Curti, Brendan D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Feng, Zipei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Montler, Ryan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gough, Michael J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fox, Bernard A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weinberg, Andrew D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Urba, Walter J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:52</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:1-10</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2015.11.009</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">52</subfield><subfield code="j">2016</subfield><subfield code="h">1-10</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Bell, R. Bryan |
| spellingShingle |
Bell, R. Bryan ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier OX40 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Head and neck cancer Elsevier CTLA-4 Elsevier PD-1 OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment |
| authorStr |
Bell, R. Bryan |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011194073 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 650 - Management & auxiliary services |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment OX40 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Head and neck cancer Elsevier CTLA-4 Elsevier PD-1 Elsevier |
| topic |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier OX40 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Head and neck cancer Elsevier CTLA-4 Elsevier PD-1 |
| topic_unstemmed |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier OX40 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Head and neck cancer Elsevier CTLA-4 Elsevier PD-1 |
| topic_browse |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier OX40 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Head and neck cancer Elsevier CTLA-4 Elsevier PD-1 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r s l rs rsl m r c mr mrc b d c bd bdc z f zf r m rm m j g mj mjg b a f ba baf a d w ad adw w j u wj wju |
| hierarchy_parent_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| hierarchy_parent_id |
ELV011194073 |
| dewey-tens |
610 - Medicine & health 650 - Management & public relations |
| hierarchy_top_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011194073 |
| title |
OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment |
| ctrlnum |
(DE-627)ELV029471567 (ELSEVIER)S1368-8375(15)00387-5 |
| title_full |
OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment |
| author_sort |
Bell, R. Bryan |
| journal |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| journalStr |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
1 |
| author_browse |
Bell, R. Bryan |
| container_volume |
52 |
| physical |
10 |
| class |
610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Bell, R. Bryan |
| doi_str_mv |
10.1016/j.oraloncology.2015.11.009 |
| dewey-full |
610 650 |
| title_sort |
ox40 signaling in head and neck squamous cell carcinoma: overcoming immunosuppression in the tumor microenvironment |
| title_auth |
OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment |
| abstract |
• Anti-OX40 is a promising antibody that is currently in early phase clinical trials for the treatment of cancer. • OX40 is highly expressed in the tumor infiltrating lymphocytes of patients with head and neck squamous cell carcinoma. • Preclinical models have suggested synergy between anti-OX40 and anti-PD1, anti-OX40 and anti-CTLA-4, as well as anti-OX40 and anti-PDL1. • Anti-OX40 is currently being tested in early phase human clinical trials, both as monotherapy and in combination with other immunotherapies, in head and neck squamous cell carcinoma. |
| abstractGer |
• Anti-OX40 is a promising antibody that is currently in early phase clinical trials for the treatment of cancer. • OX40 is highly expressed in the tumor infiltrating lymphocytes of patients with head and neck squamous cell carcinoma. • Preclinical models have suggested synergy between anti-OX40 and anti-PD1, anti-OX40 and anti-CTLA-4, as well as anti-OX40 and anti-PDL1. • Anti-OX40 is currently being tested in early phase human clinical trials, both as monotherapy and in combination with other immunotherapies, in head and neck squamous cell carcinoma. |
| abstract_unstemmed |
• Anti-OX40 is a promising antibody that is currently in early phase clinical trials for the treatment of cancer. • OX40 is highly expressed in the tumor infiltrating lymphocytes of patients with head and neck squamous cell carcinoma. • Preclinical models have suggested synergy between anti-OX40 and anti-PD1, anti-OX40 and anti-CTLA-4, as well as anti-OX40 and anti-PDL1. • Anti-OX40 is currently being tested in early phase human clinical trials, both as monotherapy and in combination with other immunotherapies, in head and neck squamous cell carcinoma. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT |
| title_short |
OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment |
| url |
https://doi.org/10.1016/j.oraloncology.2015.11.009 |
| remote_bool |
true |
| author2 |
Leidner, Rom S. Crittenden, Marka R. Curti, Brendan D. Feng, Zipei Montler, Ryan Gough, Michael J. Fox, Bernard A. Weinberg, Andrew D. Urba, Walter J. |
| author2Str |
Leidner, Rom S. Crittenden, Marka R. Curti, Brendan D. Feng, Zipei Montler, Ryan Gough, Michael J. Fox, Bernard A. Weinberg, Andrew D. Urba, Walter J. |
| ppnlink |
ELV011194073 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.oraloncology.2015.11.009 |
| up_date |
2024-07-06T21:33:28.025Z |
| _version_ |
1803866978938519552 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029471567</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623201337.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2015.11.009</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016002000024.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029471567</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(15)00387-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bell, R. Bryan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Anti-OX40 is a promising antibody that is currently in early phase clinical trials for the treatment of cancer. • OX40 is highly expressed in the tumor infiltrating lymphocytes of patients with head and neck squamous cell carcinoma. • Preclinical models have suggested synergy between anti-OX40 and anti-PD1, anti-OX40 and anti-CTLA-4, as well as anti-OX40 and anti-PDL1. • Anti-OX40 is currently being tested in early phase human clinical trials, both as monotherapy and in combination with other immunotherapies, in head and neck squamous cell carcinoma.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">OX40</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oral cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Head and neck cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CTLA-4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD-1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leidner, Rom S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Crittenden, Marka R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Curti, Brendan D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Feng, Zipei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Montler, Ryan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gough, Michael J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fox, Bernard A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weinberg, Andrew D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Urba, Walter J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:52</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:1-10</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2015.11.009</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">52</subfield><subfield code="j">2016</subfield><subfield code="h">1-10</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.398802 |